JP2010510171A5 - - Google Patents

Download PDF

Info

Publication number
JP2010510171A5
JP2010510171A5 JP2009525739A JP2009525739A JP2010510171A5 JP 2010510171 A5 JP2010510171 A5 JP 2010510171A5 JP 2009525739 A JP2009525739 A JP 2009525739A JP 2009525739 A JP2009525739 A JP 2009525739A JP 2010510171 A5 JP2010510171 A5 JP 2010510171A5
Authority
JP
Japan
Prior art keywords
antiviral agent
interferon
use according
group
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009525739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010510171A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/076435 external-priority patent/WO2008063727A2/en
Publication of JP2010510171A publication Critical patent/JP2010510171A/ja
Publication of JP2010510171A5 publication Critical patent/JP2010510171A5/ja
Pending legal-status Critical Current

Links

JP2009525739A 2006-08-21 2007-08-21 ウイルス感染症の治療のための併用療法 Pending JP2010510171A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83887206P 2006-08-21 2006-08-21
US87449806P 2006-12-13 2006-12-13
US89430707P 2007-03-12 2007-03-12
PCT/US2007/076435 WO2008063727A2 (en) 2006-08-21 2007-08-21 Combination therapy for treatment of viral infections

Publications (2)

Publication Number Publication Date
JP2010510171A JP2010510171A (ja) 2010-04-02
JP2010510171A5 true JP2010510171A5 (US20080131398A1-20080605-C00009.png) 2010-10-14

Family

ID=39426663

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009525739A Pending JP2010510171A (ja) 2006-08-21 2007-08-21 ウイルス感染症の治療のための併用療法

Country Status (6)

Country Link
US (2) US20080131398A1 (US20080131398A1-20080605-C00009.png)
EP (1) EP2054076A2 (US20080131398A1-20080605-C00009.png)
JP (1) JP2010510171A (US20080131398A1-20080605-C00009.png)
KR (1) KR20090057035A (US20080131398A1-20080605-C00009.png)
CA (1) CA2666814A1 (US20080131398A1-20080605-C00009.png)
WO (1) WO2008063727A2 (US20080131398A1-20080605-C00009.png)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008088581A2 (en) * 2006-08-02 2008-07-24 United Therapeutics Corporation Liposome treatment of viral infections
US20090252785A1 (en) * 2008-03-26 2009-10-08 University Of Oxford Endoplasmic reticulum targeting liposomes
EP2398321B1 (en) 2009-02-23 2015-11-25 United Therapeutics Corporation Iminosugars and methods of treating viral diseases
ES2562635T3 (es) * 2009-02-24 2016-03-07 United Therapeutics Corporation Iminoazúcares y métodos de tratamiento de infecciones producidas por arenavirus
KR20120059447A (ko) 2009-03-27 2012-06-08 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 콜레스테롤 수준 저하 리포좀
JP5634510B2 (ja) 2009-06-12 2014-12-03 ユナイテッド セラピューティクス コーポレイション イミノ糖ならびにブニヤウイルスおよびトガウイルス疾患を治療する方法
KR20120081990A (ko) * 2009-09-04 2012-07-20 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 이미노당 및 필로바이러스 질환의 치료 방법
US20110065753A1 (en) * 2009-09-04 2011-03-17 United Therapeutics Corporation Methods of treating poxviral infections
MX2012002486A (es) * 2009-09-04 2012-09-07 United Therapeutics Corp Metodos para tratar infecciones ortomixovirales.
AU2011261185A1 (en) 2010-06-03 2013-01-10 Pharmacyclics, Inc. The use of inhibitors of Bruton's tyrosine kinase (Btk)
US8569255B2 (en) 2011-02-02 2013-10-29 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Post-exposure therapy of influenza A infections
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
CN103826627B (zh) 2011-10-21 2016-02-24 艾伯维公司 包含至少两种直接抗病毒剂和利巴韦林的组合物在制备治疗hcv的药物中的用途
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
KR20180088926A (ko) 2012-07-24 2018-08-07 파마싸이클릭스 엘엘씨 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이
SG11201503459SA (en) 2012-11-02 2015-06-29 Pharmacyclics Inc Tec family kinase inhibitor adjuvant therapy
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
BR112018077032A2 (pt) * 2016-06-23 2019-04-02 Nutrivert Llc método para aprimorar o crescimento ou a conversão alimentar em um animal, uso de pgn, mdp ou um análogo de mdp na preparação de um medicamento e pgn, mdp ou um análogo de mdp
FR3057773B1 (fr) 2016-10-21 2020-06-19 Universite Claude Bernard Lyon 1 Nouvelles compositions antivirales pour le traitement des infections liees aux coronavirus
CA3114681A1 (en) 2018-10-05 2020-04-09 Xenotherapeutics, Inc. Xenotransplantation products and methods
US10883084B2 (en) 2018-10-05 2021-01-05 Xenotherapeutics, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6241704B1 (en) * 1901-11-22 2001-06-05 Sims Deltec, Inc. Drug pump systems and methods
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US3760984A (en) * 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US4036228A (en) * 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
GB1555654A (en) * 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
US4016880A (en) * 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4111203A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
US4203442A (en) * 1977-08-29 1980-05-20 Alza Corporation Device for delivering drug to a fluid environment
DE2834122A1 (de) * 1978-08-03 1980-02-14 Bayer Ag Verfahren zur herstellung von 6-amino-6-desoxy-l-sorbose
US4203440A (en) * 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
DE2853573A1 (de) * 1978-12-12 1980-07-03 Bayer Ag Herstellung von n-substituierten derivaten des l-desoxynojirimycins
US4210139A (en) * 1979-01-17 1980-07-01 Alza Corporation Osmotic device with compartment for governing concentration of agent dispensed from device
US4692147A (en) * 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4350155A (en) * 1980-04-02 1982-09-21 Medtronic, Inc. Body implantable medical infusion system
US4311137A (en) * 1980-04-30 1982-01-19 Sherwood Medical Industries Inc. Infusion device
DE3038901A1 (de) * 1980-10-15 1982-05-06 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von n-substituierten derivaten des 1-desoxynojirimycins
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4531937A (en) * 1983-01-24 1985-07-30 Pacesetter Systems, Inc. Introducer catheter apparatus and method of use
US4725852A (en) * 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
DE3543999A1 (de) * 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
US4865845A (en) * 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
DE3611841A1 (de) * 1986-04-09 1987-10-15 Bayer Ag Verfahren zur herstellung von 1-desoxynojirimycin und dessen n-derivaten
US4861892A (en) * 1988-02-12 1989-08-29 G. D. Searle & Co. Method for synthesis of deoxymannojirimycin
US5017563A (en) * 1988-06-23 1991-05-21 Merrell Dow Pharmaceuticals Inc. Castanospermine esters and glycosides
US4855173A (en) * 1988-08-11 1989-08-08 Dore Peter B Repair process for a fibre reinforced structure
US4910310A (en) * 1988-10-03 1990-03-20 G. D. Searle & Co. Synthesis of N-substituted 1,5-dideoxy-1,5-imino-L-fucitol derivatives
US4894388A (en) * 1988-12-22 1990-01-16 Monsanto Company Glycosidase inhibitors and use thereof
US5011929A (en) * 1989-05-15 1991-04-30 Monsanto Company Synthesis of mannojirimycin derivatives
US5100797A (en) * 1989-06-27 1992-03-31 Monsanto Company Fucosidase inhibitors
US5017704A (en) * 1989-06-27 1991-05-21 Monsanto Company Fucosidase inhibitor
US5043273A (en) * 1989-08-17 1991-08-27 Monsanto Company Phosphorylated glycosidase inhibitor prodrugs
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US4994572A (en) * 1989-10-12 1991-02-19 Monsanto Company Synthesis of nojirimycin derivatives
US4996329A (en) * 1989-10-20 1991-02-26 Monsanto Company Derivatives of 1,4-dideoxy-1,4-imino-D-mannitol and a process for their preparation
US5013842A (en) * 1990-01-22 1991-05-07 Monsanto Company Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors
US5151519A (en) * 1990-05-07 1992-09-29 G. D. Searle & Co. Process for the preparation of 1,5-(alkylimino)-1,5-dideoxy-d-glucitol and derivatives thereof
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
ES2087277T3 (es) * 1990-09-20 1996-07-16 Monsanto Co Procedimiento para producir 1-desoxinojirimicina n-sustituida.
US5200523A (en) * 1990-10-10 1993-04-06 Monsanto Company Synthesis of nojirimycin derivatives
US5137727A (en) * 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5401645A (en) * 1992-03-16 1995-03-28 Monsanto Company Process for producing n-substituted polyhydroxy nitrogen-containing heterocycles utilizing acetobacteraceae and corynebacterium
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5545143A (en) * 1993-01-21 1996-08-13 T. S. I. Medical Device for subcutaneous medication delivery
US5286877A (en) * 1993-02-01 1994-02-15 G. D. Searle & Co. Synthesis of 1,4-dideoxy-1,4-imino-L-arabinitol
US5399567A (en) * 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
DK0739205T3 (da) * 1994-01-13 2000-05-01 Searle & Co Anvendelse af N-alkylderivater af 1,5-didesoxy-1,5-imino-D-glucitol til behandling af hepatitis-B-virusinfektioner
AU1876095A (en) * 1994-02-25 1995-09-11 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
US5443450A (en) * 1994-04-29 1995-08-22 Medtronic, Inc. Medication delivery device and method of construction
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
DE19509634C1 (de) * 1995-03-17 1996-03-28 Fresenius Ag Implantierbare Infusionspumpe
US5643207A (en) * 1995-04-28 1997-07-01 Medtronic, Inc. Implantable techniques for infusing a therapeutic agent with endogenous bodily fluid
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
DK1238659T3 (da) * 1996-02-02 2005-01-24 Alza Corp Vedvarende frigivelse af et aktivt middel ved anvendelse af et implanterbart system
EP0961775B1 (en) * 1996-10-16 2004-07-14 ICN Pharmaceuticals, Inc. Purine l-nucleosides, analogs and uses thereof
ES2169880T3 (es) * 1996-10-18 2002-07-16 Vertex Pharma Inhibidores de proteasas de serina, particularmente de la proteasa ns3 del virus de la hepatitis c.
US20030100532A1 (en) * 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
GB2324223A (en) * 1997-04-11 1998-10-14 Northern Telecom Ltd Network management
US6171276B1 (en) * 1997-08-06 2001-01-09 Pharmacia & Upjohn Ab Automated delivery device and method for its operation
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
PL190267B1 (pl) * 1997-12-22 2005-11-30 Schering Corp Stała postać dawkowania do podawania doustnego zawierająca rybawirynę i sposób jej wytwarzania
US6423695B1 (en) * 1998-01-13 2002-07-23 Ribapharm, Inc. Cytokine related treatments of disease
US6689759B1 (en) * 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
DK1066247T3 (da) * 1998-03-31 2007-04-02 Vertex Pharma Inhibitorer af serinproteaser, især hepatitis C virus NS3 protease
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6440985B1 (en) * 1998-09-04 2002-08-27 Viropharma Incorporated Methods for treating viral infections
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US6308099B1 (en) * 1998-11-13 2001-10-23 Intermedics Inc. Implantable device and programmer system which permits multiple programmers
AU3595500A (en) * 1999-02-12 2000-08-29 G.D. Searle & Co. Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
US6198966B1 (en) * 1999-02-26 2001-03-06 Medtronic, Inc. Recirculating implantable drug delivery system
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US7256005B2 (en) * 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
JP2003522791A (ja) * 2000-02-14 2003-07-29 ファルマシア コーポレイション 肝炎ウイルス感染症治療用ｎ‐置換‐１，５‐ジデオキシ‐１，５‐イミノ‐ｄ‐グルシトール化合物の使用
US6689784B2 (en) * 2000-03-29 2004-02-10 Vertex Pharmaceuticals Incorporated Carbamate caspase inhibitors and uses thereof
AP2002002407A0 (en) * 2000-05-23 2002-03-31 Vertex Pharma Caspase inhibitors and uses thereof.
DE10031274A1 (de) * 2000-06-27 2002-01-10 Bosch Gmbh Robert Wischarm für Kraftfahrzeuge
GB0110832D0 (en) * 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
WO2003032946A2 (en) * 2001-10-12 2003-04-24 United Therapeutics Corporation Ph-sensitive liposomes for targeted drug delivery
US7091184B2 (en) * 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
WO2005120479A1 (en) * 2004-06-09 2005-12-22 Gpc Biotech Ag Use of selenium or a selenium salt and a retinoid acid or a retinoid in the treatment of viral hepatitis c
WO2006085141A2 (en) * 2004-08-13 2006-08-17 Migenix Inc. Compositions and methods for treating or preventing hepadnaviridae infection
US20060093577A1 (en) * 2004-10-06 2006-05-04 Migenix Inc. Combination anti-viral compositions and methods of use
MY141025A (en) * 2004-10-29 2010-02-25 Vertex Pharma Dose forms
CN101304762A (zh) * 2005-02-09 2008-11-12 米珍尼克斯公司 治疗或预防黄病毒科感染的组合物和方法
WO2008088581A2 (en) * 2006-08-02 2008-07-24 United Therapeutics Corporation Liposome treatment of viral infections

Similar Documents

Publication Publication Date Title
JP2010510171A5 (US20080131398A1-20080605-C00009.png)
JP2017535610A5 (US20080131398A1-20080605-C00009.png)
Kurimoto et al. Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities
JP2009536660A5 (US20080131398A1-20080605-C00009.png)
JP2010514786A5 (US20080131398A1-20080605-C00009.png)
JP2006524660A5 (US20080131398A1-20080605-C00009.png)
JP2008515994A5 (US20080131398A1-20080605-C00009.png)
RU2008145714A (ru) Пуриновые производные в качестве активатора аденозинового рецептора
JP2005526144A5 (US20080131398A1-20080605-C00009.png)
JP2009526034A5 (US20080131398A1-20080605-C00009.png)
JP2010526834A5 (US20080131398A1-20080605-C00009.png)
JP2008523082A5 (US20080131398A1-20080605-C00009.png)
JP2016521273A5 (US20080131398A1-20080605-C00009.png)
JP2006524225A5 (US20080131398A1-20080605-C00009.png)
JP2002519355A5 (US20080131398A1-20080605-C00009.png)
JP2006512313A5 (US20080131398A1-20080605-C00009.png)
JP2004534769A5 (US20080131398A1-20080605-C00009.png)
JP2007530577A5 (US20080131398A1-20080605-C00009.png)
JP2005508905A5 (US20080131398A1-20080605-C00009.png)
JP2007515405A5 (US20080131398A1-20080605-C00009.png)
JP2003501474A5 (US20080131398A1-20080605-C00009.png)
JP2010524932A5 (US20080131398A1-20080605-C00009.png)
RU2007108863A (ru) Производные пиразола для лечения состояний, опосредованных активацией рецептора аденозина а2в или а3
WO2006120251A1 (en) Pteridines useful as hcv inhibitors and methods for the preparation thereof
SG189985A1 (en) Inhibitors of hepatitis c virus